Lakefront Biotherapeutics (GLPGF) Liabilities from Discontinued Operations (2020 - 2023)
Lakefront Biotherapeutics' (GLPGF) quarterly Liabilities from Discontinued Operations came in at $34.5 million in Q4 2023, up 270.11% quarter-over-quarter from $9.3 million in Q1 2023.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Liabilities from Discontinued Operations (2020 - 2023) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $34.5 million the latest figure, recorded in Q4 2023.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to $34.5 million in Q4 2023; TTM through Dec 2023 was $34.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $34.5 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations was $34.5 million for Q4 2023 at Lakefront Biotherapeutics, up from $9.3 million in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at $10.6 billion in Q4 2020 and troughed at $9.3 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.40 Bn | 197.42 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.13 Bn | 124.28 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.53 Bn | 74.53 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.72 Bn | 56.54 Bn | 1.37 Bn |
| 6 | Moderna | 54.67 Bn | 49.53 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.00 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.03 Bn | 30.03 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 34.48 Mn |
| Mar 31, 2023 | 9.32 Mn |
| Dec 31, 2020 | 10.63 Bn |